Verve Therapeutics, Inc. (NASDAQ:VERV) Stake Lessened by GSA Capital Partners LLP

GSA Capital Partners LLP decreased its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) by 82.3% during the 3rd quarter, Holdings Channel.com reports. The firm owned 36,102 shares of the company’s stock after selling 167,575 shares during the quarter. GSA Capital Partners LLP’s holdings in Verve Therapeutics were worth $175,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC raised its stake in shares of Verve Therapeutics by 908.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 7,714 shares of the company’s stock worth $38,000 after buying an additional 6,949 shares in the last quarter. Creative Planning acquired a new stake in Verve Therapeutics in the 3rd quarter valued at about $50,000. PFG Investments LLC bought a new position in shares of Verve Therapeutics during the 3rd quarter valued at about $53,000. Daiwa Securities Group Inc. grew its stake in shares of Verve Therapeutics by 89.8% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,094 shares of the company’s stock worth $59,000 after purchasing an additional 5,723 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. raised its holdings in shares of Verve Therapeutics by 13.5% in the 2nd quarter. Cornercap Investment Counsel Inc. now owns 14,956 shares of the company’s stock worth $73,000 after purchasing an additional 1,778 shares in the last quarter. 97.11% of the stock is currently owned by institutional investors and hedge funds.

Verve Therapeutics Stock Up 5.4 %

Shares of NASDAQ:VERV opened at $4.85 on Monday. The company’s fifty day moving average is $5.35 and its two-hundred day moving average is $5.61. The company has a market cap of $410.60 million, a P/E ratio of -1.97 and a beta of 1.75. Verve Therapeutics, Inc. has a 12-month low of $4.30 and a 12-month high of $19.34.

Verve Therapeutics (NASDAQ:VERV) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.11. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The firm had revenue of $6.87 million during the quarter, compared to the consensus estimate of $2.75 million. During the same period in the prior year, the business earned ($0.72) EPS. The business’s revenue for the quarter was up 120.2% on a year-over-year basis. Equities research analysts anticipate that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

VERV has been the subject of a number of research reports. Royal Bank of Canada reduced their target price on shares of Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. HC Wainwright cut their target price on Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Finally, Canaccord Genuity Group increased their price target on Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.